Elvira
Elvira Balaguer Ardanuy, Sant Feliu De Llobregat ES
Patent application number | Description | Published |
---|---|---|
20150057256 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR - The present invention is directed to novel polymorphic crystal forms of a 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, methods of using them to treat respiratory diseases associated with β2 adrenergic receptor activity and a process for preparing such polymorphic crystal forms. | 02-26-2015 |
Elvira Beitler, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20100283504 | METHOD FOR FABRICATION OF A SEMICONDUCTOR ELEMENT AND STRUCTURE THEREOF - Re-programmable antifuses and structures utilizing re-programmable antifuses are presented. Such structures include a configurable interconnect circuit having at least one re-programmable antifuse, wherein the at least one re-programmable antifuse is configured to be programmed to conduct by applying a first voltage across it and is configured to be re-programmed not to conduct by applying second voltage across it, wherein the second voltage is higher than the first voltage. Other embodiments of antifuses include an initializing step prior to programming. | 11-11-2010 |
Elvira De Mejia, Urbana, IL US
Patent application number | Description | Published |
---|---|---|
20110136745 | METHOD OF SELECTING SOYBEANS WITH ENHANCED BIOACTIVITY AND COMPOSITIONS FOR REDUCING CANCER CELL VIABILITY - The invention provides a method that uses enzyme-treatment of whole soybeans or partially defatted soybeans to select soybeans with improved bioactivity or bioactivities. The invention further provides a soybean plant and seed with a non-transgenic mutation conferring enhanced bioactivity as an hydrolysate when compared to hydrolysate from other seeds, for instance in a cell-based assay, including reduced cancer cell viability; increased LDL receptor activity; reduced lipid accumulation; increased adiponectin expression; decreased FAS and LPL expression; reduced production of NO and PGE | 06-09-2011 |
Elvira Djonovic, Hicksville, NY US
Patent application number | Description | Published |
---|---|---|
20130258903 | SYSTEMS AND METHODS FOR MODELING TELECOMMUNICATION SWITCH INVESTMENTS - In one of many possible embodiments, a system is provided for modeling telecommunication switch investments. The exemplary system includes a telecommunication switch modeling application configured to determine equipment quantities having capacity to satisfy switch design parameters descriptive of at least one model telecommunication switch, and calculate model investments associated with the equipment quantities. The exemplary system also includes a telecommunication switch investment modeling application configured to weight the model investments in accordance with at least one of a network parameter descriptive of an actual telecommunication switch and a “what-if” input descriptive of a hypothetical telecommunication switch configuration to form weighted investments that are specific to at least one of the actual telecommunication switch and the hypothetical telecommunication switch configuration. | 10-03-2013 |
Elvira Favoino, Casamassima IT
Patent application number | Description | Published |
---|---|---|
20120009194 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma. | 01-12-2012 |
20140010811 | ANTIBODIES TO ENDOPLASMIN AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind endoplasmin. In some embodiments these antibodies are fully human. Recombinant nucleic acids encoding these antibodies, expression vectors including these nucleic acids, and host cells transformed with these expression vectors are also disclosed herein. In several embodiments the disclosed antibodies are of use for detecting and/or treating tumors that express endoplasmin, such as melanoma, breast cancer, head and neck squamous cell carcinoma, renal cancer, lung cancer, glioma, bladder cancer, ovarian cancer or pancreatic cancer. In one example, the tumor is a melanoma. | 01-09-2014 |
20140234324 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 - Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720. | 08-21-2014 |
Elvira Favoino, Bari IT
Patent application number | Description | Published |
---|---|---|
20120148598 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS GRP94 - Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720. | 06-14-2012 |
Elvira Favoino, Casamassima Bari IT
Patent application number | Description | Published |
---|---|---|
20130259873 | METHODS FOR TREATING A TUMOR USING AN ANTIBODY THAT SPECIFICALLY BINDS HMW-MAA - Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds high molecular weight melanoma associated antigen (HMW-MAA), also known as CSPG4; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720. | 10-03-2013 |
Elvira Garza Gonzalez, Guadalupe MX
Patent application number | Description | Published |
---|---|---|
20100159448 | METHOD FOR DETECTION AND MULTIPLE, SIMULTANEOUS QUANTIFICATION OF PATHOGENS BY MEANS OF REAL-TIME POLYMERASE CHAIN REACTION - A method for the detection and multiple, simultaneous quantification of any combination of | 06-24-2010 |
20110268842 | BIFIDOBACTERIA THAT PRODUCES FOLIC ACID, FOOD COMPOSITION AND USE OF SAID BIFIDOBACTERIA - A bacterial strain of human origin belonging to the species | 11-03-2011 |
Elvira Gittler, Jena DE
Patent application number | Description | Published |
---|---|---|
20140247481 | OPTICAL COMPONENT FOR THE IR RANGE WITH STRESS-COMPENSATED COATING - A method for designing an optical component for the IR range in which its desired technical characteristics are determined, and the optical component is simulated. The simulated optical component has a layer sequence of layers which are stacked one upon the other and have at least one low-index layer whose refractive index lies in a range from 1.35 to 1.7 and a high-index layer whose refractive index lies in a range from 3 to 5. Subsequently, a modified simulated optical component is generated in that at least one low-index layer of the simulated optical component is divided into at least two partial layers and a mid-index layer is inserted between at least two of the partial layers. The layer thicknesses of the modified simulated optical component are adapted by means of a further simulation such that the modified simulated optical component has the desired technical characteristics. | 09-04-2014 |
20150109663 | DLC Coating for an Optical IR Component and Optical IR Component Having Said DLC Coating - A multispectral optical IR component with a hybrid coating DLC coating and an antireflection coating. The DLC coating has at least an outer layer with a first modulus of elasticity and an inner layer with a second modulus of elasticity which are arranged one above the other on the antireflection coating. The value of the first modulus of elasticity is greater than the value of the second modulus of elasticity. There is a transmissivity to IR radiation of at least 80% over a first determined wavelength range and over a second determined wavelength range. The first determined wavelength range lies in the range of mid-wavelength IR radiation, and the second determined wavelength range lies in the range of long-wavelength IR radiation. | 04-23-2015 |
Elvira Jimenez Schreck, Chicago, IL US
Patent application number | Description | Published |
---|---|---|
20140335755 | STUFFED ANIMAL WITH STORAGE POUCH FOR PLASTIC BAGS OR THE LIKE - A storage pouch is adapted for use with an animal body comprising a trunk having a waist and a shoulder. The storage pouch comprises a generally tubular shape garment comprising a continuous fabric panel defining an interior storage space having a top end opening and a bottom end opening. A zippered opening in the panel provides selective access to the storage space. A circular waistband is at the top end opening and is receivable on the trunk waist. First and second straps each have opposite ends secured to a front and a back of the waistband to suspend the garment from the animal body shoulder. A circular cuff is at the bottom end opening. A pair of semi-circular fabric pieces is secured to the cuff to provide a slot opening into the storage space. Articles to be stored can be inserted through the zippered opening and withdrawn through the slotted opening. | 11-13-2014 |
Elvira Lang, Heilbronn DE
Patent application number | Description | Published |
---|---|---|
20140328992 | TOOTH-FRIENDLY SUGAR CONFECTIONERY - The present invention relates to a tooth-friendly sugar confectionery based on a gelatin gel, which includes approximately 1 to approximately 15 weight % of gelatin, wherein the sugar confectionery includes trehalose and a resistant dextrin. | 11-06-2014 |
Elvira Luongo, Torre Le Nocelle (av) IT
Patent application number | Description | Published |
---|---|---|
20110212904 | GALACTOSYLATED PRO-DRUGS OF NON-STEROIDAL ANTI-INFLAMMATORIES WITH IMPROVED PHARMACOKINETIC CHARACTERISTICS AND REDUCED TOXICITY OF THE STARTING DRUG - Pro-drugs of all non-steroidal anti-inflammatories with free acid function derivatized with an ester group, which have the general structural formula given below (I) where A is: aspirin, diflunisal, benorylate, ibufenac, diclofenac, indomethacin, sulindac, ketorolac, ibuprofen, naproxen, ketoprofen, fenoprofen, flurbiprofen, mefenamic acid, meclof enamic acid, flufenamic acid, niflumic acid, and where in the ester group R can be a sugar (amongst which aldose, or ketose pentose, or esose selected from a group of D- and L-enantioiuers of ribose, glucose, galactose, mannose, arabinose, xilose, allose, altrose, gulose, idose and talose and substituted derivatives thereof, such as glucosamine, galactosamine, N-acetyl glucosamine, N-acetyl galactosamine, N-acetyl ribosamine), a disaccharide, a trisaccharide or an oligosaccharide. | 09-01-2011 |
Elvira Mavric, Holzminden DE
Patent application number | Description | Published |
---|---|---|
20090041872 | Encapsulated Vaccinium Extracts with Balanced Gastrointestinal Release - The invention relates to | 02-12-2009 |
Elvira Parravicini, Bronxville, NY US
Elvira Perless, Oberriexingen DE
Patent application number | Description | Published |
---|---|---|
20150120167 | METHOD AND APPARATUS FOR EVALUATING ABNORMAL COMBUSTION EVENTS OF AN INTERNAL COMBUSTION ENGINE OF A MOTOR VEHICLE BY REGRESSION CALCULATION OF A PHYSICAL VARIABLE - A method for evaluating abnormal combustion events of an internal combustion engine of a motor vehicle by regression calculation of a physical reference variable, in which method a recognition variable of the abnormal combustion event is calculated from a measured sensor signal. In a method with which abnormal combustion processes of the internal combustion engine can be reliably recognized and classified at all operating points, a stepwise system is used for regression calculation of the recognition variable, in which system at least one reference variable that corresponds to a measured reference variable of the sensor signal is calculated from the sensor signal. | 04-30-2015 |
Elvira Pistolesi, Milano IT
Patent application number | Description | Published |
---|---|---|
20100179107 | N-ACYL-PHOSPHATIDYL-ETHANOLAMINES AND/OR MIXTURES OF N-ACYL-ETHANOLAMINES WITH PHOSPHATIDIC ACIDS OR LYSOPHOSPHATIDIC ACIDS - Pharmaceutical, cosmetic and dietetic compositions and functional foods, constituted by: A) phospholipid mixtures containing N-acyl-phosphatidyl-ethanolamines (NAPEs) and/or B) phospholipid mixtures containing N-acyl-ethanol amines (NAEs) together with phosphatidic acids (PAs) and/or lysophosphatidic acids (LPAs) with the proviso that said N-acyl-phosphatidyl-ethanolamines (NAPEs) do not include N-oleoyl-phosphatidyl-ethanolamine. New phosphobioflavonic complexes of NAPE or NAE with one or more bioflavonoids are also disclosed. | 07-15-2010 |
Elvira Rempt, Wertheim DE
Patent application number | Description | Published |
---|---|---|
20100129593 | Binder-consolidated textile fabric, method for producing it, and use thereof - The invention relates to a novel binder system and its use for the consolidation of textile fabrics, and to products containing such consolidated textile fabrics. The materials of the invention are suitable for the manufacture of lining materials which can be used in the manufacture of sarking membranes, roofing sheets and water-proof sheetings, in particular of coated sarking membranes, roofing sheets and water-proof sheetings, or in the manufacture of carpets and PVC floorings as a textile backing or as a textile reinforcement. | 05-27-2010 |
20150044414 | FIBRE MAT AND PRODUCTS CONTAINING FIBRE MATS - A hybrid fibre mat comprises glass fibres, polymer fibres and binding agents, the glass fibres having a mean diameter of between 6 and 13 μm and a mean length of between 6 and 15 mm, the polymer fibres being staple fibres having a mean fineness of between 0.2 and 0.6 dtex and a mean length of between 2 and 4 mm and the percentage by weight of the polymer fibres being between 5 and 20% of the dry fibre mat. Such a hybrid fibre mat being suitable in particular as a covering for interior elements, a ceiling panel or other interior cladding elements and, provided with an impregnation (for example plastisol), in particular as a structural layer of a cushioned vinyl floor covering. For the production thereof, preferably water which contains the glass fibres and the polymer fibres is passed in a circuit through a band screen, the fibre mixture in the form of a fibre layer with a predetermined layer thickness is deposited on the band screen, excess circuit water is removed from the fibre layer, binding agent is added to the fibre layer and the fibre layer to which binding agent has been added is dried. | 02-12-2015 |
Elvira Sonnendorfer US
Patent application number | Description | Published |
---|---|---|
20140375456 | PUSH HANDLE FOR A SHOPPING TROLLEY - A push handle for a shopping trolley contains a holder for a mobile telecommunications terminal, in particular a smartphone. The holder includes a mounting for the telecommunications terminal and a pivot joint by which the mounting can be pivoted between a home position when it rests against the push handle and a holding position when it extends away from the push handle. | 12-25-2014 |
Elvira Stesikova, Ypsilanti, MI US
Patent application number | Description | Published |
---|---|---|
20100280162 | DISPERSING AGENT - A dispersing agent and a composition including a pigment and the dispersing agent are provided. The dispersing agent includes a branched alcohol alkoxylate having the following formula (I): | 11-04-2010 |
Elvira Tjipto, Victoria AU
Patent application number | Description | Published |
---|---|---|
20090047517 | MULTILAYER POLYMER FILMS - The invention relates to a multilayer polymer assembly comprising polymer layers covalently bonded together by crosslinks comprising a cyclic moiety, and to processes for the preparation thereof. | 02-19-2009 |
Elvira Tjipto, Melbourne AU
Patent application number | Description | Published |
---|---|---|
20090023155 | Polyelectrolyte multilayer films at liquid-liquid interfaces and methods for providing and using same - The present invention is directed to methods for providing a polyelectrolyte multilayer film at a liquid-liquid interface. Such methods include steps of sequentially-depositing layers of cationic and anionic polyelectrolytes at a liquid-liquid interface that is formed between immiscible first and second liquids whereby a polyelectrolyte multilayer film is provided at the liquid-liquid interface. In certain preferred embodiments, the first liquid is an aqueous solution and the second liquid is a liquid crystal. In alternative embodiments, the first liquid is an aqueous solution and the second liquid is an oil. The invention further encompasses polyelectrolyte multilayer films provided by the disclosed methods as well as applications utilizing such materials. | 01-22-2009 |
20100196947 | Polyelectrolyte Multilayer Films At Liquid-Liquid Interfaces - The present invention is directed to methods for providing a polyelectrolyte multilayer film at a liquid-liquid interface. Such methods include steps of sequentially-depositing layers of cationic and anionic polyelectrolytes at a liquid-liquid interface that is formed between immiscible first and second liquids whereby a polyelectrolyte multilayer film is provided at the liquid-liquid interface. In certain preferred embodiments, the first liquid is an aqueous solution and the second liquid is a liquid crystal. In alternative embodiments, the first liquid is an aqueous solution and the second liquid is an oil. The invention further encompasses polyelectrolyte multilayer films provided by the disclosed methods as well as applications utilizing such materials. | 08-05-2010 |
Elvira Wolf, Krefeld DE
Patent application number | Description | Published |
---|---|---|
20080202381 | Adhesive Composition - There is provided an adhesive composition comprising a carrier starch and a secondary starch characterised in that the carrier starch: —comprises, on a dry weight basis, less than 50% pre-gelatinised starch; and has a higher alkali sensitivity than the secondary starch. There is further provided a process for preparing such and adhesive composition. | 08-28-2008 |
Elvira Zini, Buenos Aires AR
Patent application number | Description | Published |
---|---|---|
20140357678 | COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM - A pharmaceutically acceptable salt, prodrug or derivative compound of the formula I, wherein R | 12-04-2014 |